We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Responds to Concerns from Lawmakers on Opioid Black Boxes
FDA Responds to Concerns from Lawmakers on Opioid Black Boxes
The FDA may be reconsidering its policy of only requiring black box warnings on extended-release opioids, telling lawmakers that a citizen petition to require the same warnings for immediate-release opioids is under “active consideration.”